Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M LopezC L Maini

Abstract

We conducted a randomized trial to evaluate primarily the cardioprotective effect of dexrazoxane (DEX) in patients with advanced breast cancer and soft tissue sarcomas (STS) treated with high-dose epirubicin (EPI). We wished also to determine the value of radioimmunoscintigraphy (RIS) in the assessment of anthracycline cardiotoxicity. Patients with breast cancer (n = 95) or STS (n = 34) received EPI 160 mg/m2 by intravenous (I.V.) bolus every 3 weeks with or without DEX 1,000 mg/m2 I.V. Cardiac monitoring included multigated radionuclide (MUGA) scans with determination of resting left ventricular ejection fraction (LVEF), and RIS with indium 111 antimyosin monoclonal antibodies. In either disease, antitumor response rates, time to progression, and survival did not significantly differ between the two arms. There was little difference in noncardiac toxicity for the two treatment groups. All methods of cardiac evaluation clearly documented the cardioprotective effect of DEX. Four patients developed congestive heart failure (CHF), all in the EPI arm. The decrease in LVEF from baseline was significantly greater in the control group. An abnormal antimyosin uptake was observed early in both arms and progressively increased during tre...Continue Reading

Citations

Nov 28, 2007·Experimental Biology and Medicine·Snezana K BjelogrlicViktor Jovic
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robin L Jones
Sep 5, 2015·Heart Failure Reviews·Angela Y HigginsJames D Chang
Jun 7, 2018·NPJ Precision Oncology·Xinqiang HanWendi Liu
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo LopezSilvia Carpano
Dec 15, 2005·British Journal of Haematology·Karlijn A WoutersSteven E Lipshultz
Oct 21, 2004·Journal of the National Cancer Institute·Ramzi DagherRichard Pazdur
Sep 19, 2014·Current Opinion in Oncology·Manali BhaveSteven T Rosen
Dec 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saro H ArmenianDaniel Lenihan
Oct 16, 1999·British Journal of Haematology·G Levitt
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claudia LangebrakeJörg Ritter
Jun 28, 2005·Paediatric Drugs·Valeriano C SimbreSteven E Lipshultz
Mar 28, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Thomas L'EcuyerRichard Vander Heide
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elly V BarryLewis B Silverman
Apr 9, 2010·Anti-cancer Drugs·Sandra GeigerHans-Joachim Stemmler
Aug 12, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Franco TestoreGiuseppina Bosso
Aug 21, 2013·Cancer Chemotherapy and Pharmacology·Duncan T VincentYuichiro J Suzuki
May 20, 2016·British Journal of Clinical Pharmacology·Folefac AminkengUNKNOWN CPNDS Clinical Practice Recommendations Group
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister
Jun 3, 2011·Current Oncology Reports·Sherif S Morgan, Lee D Cranmer
Aug 20, 2009·Cardiology in Review·Kuldeep Maradia, Maya Guglin
Nov 23, 2006·Cardiovascular Drugs and Therapy·Eyal RamuHerzl Schwalb
Nov 28, 2013·Human & Experimental Toxicology·M Pacifico de Freitas SegredoAla Ferreira
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Nov 6, 2010·The Oncologist·Dana M SepeFrank M Balis
Nov 11, 2016·Oxidative Medicine and Cellular Longevity·Robin K KuriakoseLei Xi
Nov 11, 2015·Circulation·Ronald M Witteles, Xavier Bosch
Mar 3, 2012·Current Heart Failure Reports·Amir Y Shaikh, Jeffrey A Shih
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.